KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics
Authors
Keywords
-
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 186, Issue -, Pages 103987
Publisher
Elsevier BV
Online
2023-04-13
DOI
10.1016/j.critrevonc.2023.103987
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
- (2022) Sai-Hong Ignatius Ou et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS: A Druggable Target in Colon Cancer Patients
- (2022) Francesca Negri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
- (2022) Luis A Diaz et al. LANCET ONCOLOGY
- Cell line models for drug discovery in PIK3CA-mutated colorectal cancers
- (2022) Ioannis A. Voutsadakis MEDICAL ONCOLOGY
- Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers
- (2022) Iiris Ukkola et al. VIRCHOWS ARCHIV
- Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
- (2022) Erika Durinikova et al. CLINICAL CANCER RESEARCH
- Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer
- (2022) Elaine S. Tan et al. Targeted Oncology
- Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
- (2022) Jingran Ji et al. OncoTargets and Therapy
- KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
- (2022) Meagan B. Ryan et al. Cell Reports
- Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
- (2022) A. Boccaccino et al. ESMO Open
- The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers
- (2022) Ioannis A. Voutsadakis Journal of Clinical Medicine
- KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
- (2022) Sahar F. Bannoura et al. Frontiers in Oncology
- Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
- (2022) Daniele Lavacchi et al. Frontiers in Oncology
- Targeting KRASG12C in colorectal cancer: the beginning of a new era
- (2022) D. Ciardiello et al. ESMO Open
- PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells
- (2021) Laura Rosa Mangiapane et al. GUT
- Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
- (2021) James M. Cleary et al. CLINICAL CANCER RESEARCH
- The landscape of PI3KCA mutations in colorectal cancer
- (2021) Ioannis A. Voutsadakis Clinical Colorectal Cancer
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- (2021) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories
- (2021) Claire Bocciarelli et al. HUMAN PATHOLOGY
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
- (2021) Salvatore Siena et al. LANCET ONCOLOGY
- Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer
- (2021) Jonathan M. Loree et al. CLINICAL CANCER RESEARCH
- Tissue-Agnostic Drug Development: A New Path to Drug Approval
- (2021) Kyaw Z. Thein et al. Cancer Discovery
- TP53 Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer
- (2021) Minggui Pan et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
- (2021) Xiaolun Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
- (2021) Marwan G Fakih et al. LANCET ONCOLOGY
- Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry
- (2021) Anas Alawawdeh et al. Targeted Oncology
- Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype
- (2021) Jiayin Deng et al. Cell Death & Disease
- Colorectal cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- HER2 as a predictive biomarker and treatment target in colorectal cancer
- (2020) Astrid De Cuyper et al. Clinical Colorectal Cancer
- Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
- (2020) Eyal Meiri et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
- (2020) Vito Amodio et al. Cancer Discovery
- Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
- (2020) Alessandro Ottaiano et al. Cancers
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
- (2020) Andrea Sartore-Bianchi et al. ESMO Open
- Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib
- (2020) Sanne C. F. A. Huijberts et al. BRITISH JOURNAL OF CANCER
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current advancements and future perspectives of immunotherapy in colorectal cancer research
- (2020) Chandra Kishore et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
- (2019) Giovanni Randon et al. Scientific Reports
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
- (2019) A B Schrock et al. ANNALS OF ONCOLOGY
- Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations
- (2019) Jai-Hee Moon et al. BRITISH JOURNAL OF CANCER
- Mechanisms of Innate and Acquired Resistance to Anti-EGFR therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies
- (2019) Christine M. Parseghian et al. CLINICAL CANCER RESEARCH
- G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer
- (2019) Tamuro Hayama et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer
- (2019) Yijun Gao et al. Cancer Discovery
- Colonic Adenocarcinomas Harboring NTRK Fusion Genes
- (2019) Jerzy Lasota et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer
- (2019) Yakup Ergun et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
- (2018) Kentaro Sawada et al. Clinical Colorectal Cancer
- Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
- (2018) Ye-Lim Park et al. INTERNATIONAL JOURNAL OF CANCER
- MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers
- (2018) Stephanie L. Fricke et al. MOLECULAR CANCER THERAPEUTICS
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer
- (2017) Robin M.J.M. van Geel et al. Cancer Discovery
- ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
- (2017) Anna-Lena Geißler et al. Oncotarget
- A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
- (2017) Grace R. Anderson et al. Cell Reports
- Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer
- (2016) Michael S Lee et al. BRITISH JOURNAL OF CANCER
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer
- (2016) Andrew Rankin et al. ONCOLOGIST
- BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
- (2016) Soo Kyung Nam et al. PLoS One
- Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer
- (2016) L. Zhang et al. Science Translational Medicine
- ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
- (2016) Chris T. Williamson et al. Nature Communications
- Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer
- (2016) Bernardo Queralt et al. Oncotarget
- Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
- (2016) Marios Giannakis et al. Cell Reports
- Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
- (2015) J. Randolph Hecht et al. CANCER TREATMENT REVIEWS
- Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer
- (2015) M. Raja et al. MOLECULAR CANCER THERAPEUTICS
- CRISPR-Cas9–based target validation for p53-reactivating model compounds
- (2015) Michael Wanzel et al. Nature Chemical Biology
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer
- (2015) RAFAŁ STEC et al. Oncology Letters
- Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma
- (2013) Karen-Lise G. Spindler et al. ACTA ONCOLOGICA
- Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens
- (2013) K. Ng et al. CLINICAL CANCER RESEARCH
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
- (2013) Erika Martinelli et al. INTERNATIONAL JOURNAL OF CANCER
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations
- (2013) P. Ganesan et al. MOLECULAR CANCER THERAPEUTICS
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Absolute quantification of somatic DNA alterations in human cancer
- (2012) Scott L Carter et al. NATURE BIOTECHNOLOGY
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation